Compare Gilead Sciences, Inc. (GILD) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tyson Foods, Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.11 (market cap $163.51B), while Tyson Foods, Inc. trades at $57.99 (market cap $20.24B). The key difference: Gilead Sciences, Inc. is far larger — about 8.1× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| GILD | TSN | |
|---|---|---|
Market Cap | $163.51B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $68.75 |
52-Week Low | $108.22 | $50.72 |
Enterprise Value | $178.05B | $27.82B |
Dividend Yield | 2.49% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Tyson Foods (TSN) trades at $57.48, down 0.76% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed fundamentals with a low P/S ratio of 0.37 and P/B of 1.12, but elevated P/E of 45.25 reflects thin net margins of 0.81%. Recent earnings have been inconsistent, beating estimates in Q3 2025 and Q1 2026 but missing in Q4 2025. The company maintains steady dividends and is focusing on growth in prepared foods.
The outlook presents a value opportunity with a consensus price target of $68.80 offering ~20% upside, supported by 50% analyst buy ratings. However, risks include volatile earnings, compressed profit margins, and significant debt load. The bearish technical picture suggests near-term pressure, while strategic initiatives in value-added products could drive long-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
